Similar conclusions were drawn from other studies, including in MSI CRC or different cancer types, promulgating high levels of stromal TGF-β signalling as a therapeutic target as well as a prognostic and predictive biomarker in the context of (ICI) immunotherapy [250,251,252,253,254,255,256,257,258,259]. The gene discussed is TGFB1; the disease is cancer.